Two men from Connecticut walk into a hotel.
No, it’s not the start of a joke. Rather, it’s the origin story of Lumeda Inc., a Rocky Hill startup with a mission of reshaping the treatment of lung cancer.
Paul Sanders, co-founder of Lumeda, describes the meeting of Connecticut photonics experts and western New York oncology innovators as little short of serendipity. But the result is a technology that may soon enable more people to survive non-small cell lung cancer.
Oncologists at Buffalo’s Roswell Park cancer research campus recognize focused light could be used to improve surviving tissue at the site of surgery to remove a cancerous lung tumor. The challenge was focusing the light and delivering a consistent level of therapy.